Daewoong Pharma Gets Nod for Fexuclue H. pylori Eradication Indication
- Fexuclue 40mg (fexuprazan) gets additional indication for H. pylori eradication combination therapy
- Approval date: April 30, 2026 by Ministry of Food and Drug Safety
- About 50% of world population infected with H. pylori; new indication expected to provide more treatment options
- Originally approved as Korea's 34th new drug in 2021; this expansion likely to boost market
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Management Issues Related to Investment Decisions (Major Management Issues of Subsidiary) (Addition of Indication for Fexuclue Tab: Domestic Product Approval for Antibiotic Combination Therapy for Helicobacter Pylori Eradication)
- Company: Daewoong (003090)
- Submission: Daewoong Co., Ltd.
- Receipt: 04-30-2026
- Under KRX KOSPI Market Division